

# Annika Å-hrfelt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1888994/publications.pdf>

Version: 2024-02-01

41  
papers

4,568  
citations

186265

28  
h-index

315739

38  
g-index

41  
all docs

41  
docs citations

41  
times ranked

6521  
citing authors

#	ARTICLE	IF	CITATIONS
1	Full-length and C-terminal neurogranin in Alzheimer's disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 168.	6.2	7
2	Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer's and Parkinson's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 82.	6.2	51
3	Mass Spectrometric Analysis of Lewy Body-Enriched $\alpha$ -Synuclein in Parkinson's Disease. <i>Journal of Proteome Research</i> , 2019, 18, 2109-2120.	3.7	49
4	Detection of $\alpha$ -Synuclein in Biological Samples Using Mass Spectrometry. <i>Methods in Molecular Biology</i> , 2019, 1948, 209-220.	0.9	4
5	A Novel ELISA for the Measurement of Cerebrospinal Fluid SNAP-25 in Patients with Alzheimer's Disease. <i>Neuroscience</i> , 2019, 420, 136-144.	2.3	25
6	Evolution of cerebrospinal fluid total $\alpha$ -synuclein in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 49, 4-8.	2.2	31
7	Expression and secretion of synaptic proteins during stem cell differentiation to cortical neurons. <i>Neurochemistry International</i> , 2018, 121, 38-49.	3.8	20
8	Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders. <i>Proteomics - Clinical Applications</i> , 2017, 11, 1700100.	1.6	28
9	Validation of a new assay for $\alpha$ -synuclein detection in cerebrospinal fluid. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 254-260.	2.3	6
10	[P1 <sup>221</sup> ]: EXPRESSION AND SECRETION OF SYNAPTIC PROTEINS DURING DIFFERENTIATION OF PLURIPOTENT STEM CELLS TO CORTICAL NEURONS. <i>Alzheimer's and Dementia</i> , 2017, 13, P328.	0.8	0
11	The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 41.	6.2	121
12	CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. <i>Lancet Neurology</i> , The, 2016, 15, 673-684.	10.2	1,413
13	Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease. <i>Movement Disorders</i> , 2016, 31, 898-905.	3.9	136
14	Increased Cerebrospinal Fluid Levels of Ubiquitin Carboxyl-Terminal Hydrolase L1 in Patients with Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2016, 6, 283-294.	1.3	33
15	Targeting LAMP2 in human cerebrospinal fluid with a combination of immunopurification and high resolution parallel reaction monitoring mass spectrometry. <i>Clinical Proteomics</i> , 2016, 13, 4.	2.1	22
16	Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2016, 11, 3.	10.8	236
17	Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1587-1595.	3.0	73
18	The Gothenburg MCI study: Design and distribution of Alzheimer's disease and subcortical vascular disease diagnoses from baseline to 6-year follow-up. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2016, 36, 114-131.	4.3	67

#	ARTICLE	IF	CITATIONS
19	Alzheimer's disease's subcortical vascular disease spectrum in a hospital-based setting: Overview of results from the Gothenburg MCI and dementia studies. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2016, 36, 95-113.	4.3	42
20	CSF biomarkers and clinical progression of Parkinson disease. <i>Neurology</i> , 2015, 84, 57-63.	1.1	178
21	Explorative and targeted neuroproteomics in Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2015, 1854, 769-778.	2.3	41
22	Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 1180-1190.	0.8	254
23	Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. <i>Neurobiology of Aging</i> , 2015, 36, 2587-2596.	3.1	30
24	Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease. <i>JAMA Neurology</i> , 2015, 72, 1175.	9.0	148
25	Targeting Synaptic Pathology with a Novel Affinity Mass Spectrometry Approach. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 2584-2592.	3.8	26
26	SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2014, 9, 53.	10.8	216
27	Metabolite and Peptide Levels in Plasma and CSF Differentiating Healthy Controls from Patients with Newly Diagnosed Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2014, 4, 549-560.	2.8	99
28	Levels of cerebrospinal fluid $\alpha$ -synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 25.	6.2	169
29	P2-110: ELEVATED CEREBROSPINAL FLUID LEVELS OF NEUROGRANIN IN ALZHEIMER'S DISEASE. , 2014, 10, P511-P511.		0
30	P2-101: EVALUATION OF THE PRESYNAPTIC PROTEIN SNAP-25 AS A NOVEL CEREBROSPINAL FLUID MARKER FOR SYNAPTIC PATHOLOGY IN ALZHEIMER'S DISEASE. , 2014, 10, P508-P508.		0
31	Evaluation of the Cerebrospinal Fluid Amyloid- $\beta$ <sub>1-42</sub> /Amyloid- $\beta$ <sub>1-40</sub> Ratio Measured by Alpha-LISA to Distinguish Alzheimer's Disease from Other Dementia Disorders. <i>Dementia and Geriatric Cognitive Disorders</i> , 2013, 36, 99-110.	1.5	45
32	Soluble amyloid precursor protein $\beta$ and $\beta$ in CSF in Alzheimer's disease. <i>Brain Research</i> , 2013, 1513, 117-126.	2.2	43
33	Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders. <i>Archives of Neurology</i> , 2012, 69, 1445.	4.5	407
34	Characteristic clinical presentation and CSF biomarker pattern in cerebral small vessel disease. <i>Journal of the Neurological Sciences</i> , 2012, 322, 192-196.	0.6	25
35	An online nanoESI-FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid $\beta$ and amyloid precursor protein in human and cat cerebrospinal fluid. <i>Journal of Mass Spectrometry</i> , 2012, 47, 591-603.	1.6	78
36	Screening for New Biomarkers for Subcortical Vascular Dementia and Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2011, 1, 31-42.	1.3	35

#	ARTICLE	IF	CITATIONS
37	Identification of Novel $\alpha$ -Synuclein Isoforms in Human Brain Tissue by using an Online NanoLC-ESI-FTICR-MS Method. <i>Neurochemical Research</i> , 2011, 36, 2029-2042.	3.3	99
38	Identification of novel N-terminal fragments of amyloid precursor protein in cerebrospinal fluid. <i>Experimental Neurology</i> , 2010, 223, 351-358.	4.1	37
39	Expression of <i>Pisum sativum</i> SAD polypeptides in production hosts and in planta: Tetrameric organization of the protein. <i>Protein Expression and Purification</i> , 2009, 63, 18-25.	1.3	3
40	Cerebrospinal fluid $\alpha$ -synuclein in neurodegenerative disorders – A marker of synapse loss?. <i>Neuroscience Letters</i> , 2009, 450, 332-335.	2.1	194
41	Transient Inflammation in Neurogenic Regions after Irradiation of the Developing Brain. <i>Radiation Research</i> , 2009, 171, 66-76.	1.5	77